Table 1.
Baseline Characteristics by Status of Primary Malignancy Endpoint
| No Malignancy (n = 16,238)∗ | Malignancy (n = 1,470) | p Value | |
|---|---|---|---|
| Age, yrs | 62.8 (56.5, 70.7) | 66.8 (60.3, 74.0) | <0.001 |
| Body mass index, kg/m2 | 27.6 (24.9, 30.9) | 27.3 (24.7, 30.7) | 0.051 |
| Weight, kg | 81.2 (71.0, 92.7) | 81.2 (72.0, 92.5) | 0.37 |
| Male | 12,231 (75.3) | 1,183 (80.5) | <0.001 |
| Caucasian | 13,543 (83.4) | 1,324 (90.1) | <0.001 |
| Region of enrollment | |||
| North America | 6,164 (38.0) | 613 (41.7) | 0.005 |
| Western Europe | 6,428 (39.6) | 654 (44.5) | <0.001 |
| Eastern Europe | 1,330 (8.2) | 77 (5.2) | <0.001 |
| Asia Pacific | 822 (5.1) | 53 (3.6) | 0.014 |
| South America | 1,494 (9.2) | 73 (5.0) | <0.001 |
| Coexisting conditions | |||
| Diabetes | 4,412 (27.2) | 383 (26.1) | 0.36 |
| Hypertension | 9,973 (61.4) | 872 (59.3) | 0.11 |
| Heart failure | 700 (4.3) | 66 (4.5) | 0.75 |
| Peripheral arterial disease | 869 (5.4) | 115 (7.8) | <0.001 |
| Current smoking | 5,290 (32.6) | 547 (37.2) | <0.001 |
| Previous myocardial infarction | 3,375 (20.8) | 327 (22.2) | 0.19 |
| Previous percutaneous coronary intervention | 3,159 (19.5) | 306 (20.8) | 0.21 |
| Previous coronary artery bypass graft | 1,480 (9.1) | 160 (10.9) | 0.025 |
| Medications at index acute coronary syndromes | |||
| Lipid-lowering therapy | 5,730 (35.3) | 543 (37.0) | 0.20 |
| Statin | 5,564 (34.3) | 527 (35.9) | 0.21 |
| Aspirin | 6,830 (42.1) | 632 (43.1) | 0.48 |
| Creatinine clearance, ml/min | 85.0 (66.1, 107.6) | 80.7 (63.5, 98.8) | <0.001 |
| TRS2P score >3 | 1,354 (8.5) | 152 (10.5) | 0.011 |
| Type of index event | |||
| MI with ST-segment elevation | 4,634 (28.5) | 451 (30.7) | 0.083 |
| MI without ST-segment elevation | 7,676 (47.3) | 704 (47.9) | 0.66 |
| Unstable angina | 3,924 (24.2) | 315 (21.4) | 0.018 |
| Laboratory values at index event | |||
| LDL-C, mg/dl | 95.0 (79.0, 110.0) | 93.8 (78.0, 109.7) | 0.23 |
| HDL-C, mg/dl | 40.0 (33.0, 49.0) | 39.1 (33.0, 48.7) | 0.38 |
| Triglycerides, mg/dl | 120.0 (85.0, 171.8) | 121.2 (85.9, 176.2) | 0.50 |
| Hs-CRP, mg/l | 5.1 (2.0, 17.7) | 5.3 (2.5, 16.1) | 0.46 |
| Hemoglobin A1c, % | 6.1 (5.6, 7.3) | 6.1 (5.7, 7.0) | 0.81 |
| Medications at time of randomization | |||
| Aspirin | 15,770 (97.1) | 1,421 (96.7) | 0.39 |
| Beta-blocker | 14,171 (87.3) | 1,277 (86.9) | 0.69 |
| ACEI/ARB inhibitor | 12,293 (75.7) | 1,082 (73.7) | 0.08 |
| Thienopyridine | 14,067 (86.6) | 1,291 (87.9) | 0.18 |
Values are median (25th, 75th percentiles) or n (%). Wilcoxon rank-sum test of differences between with and without primary malignancies for continuous variables. Chi-square test of frequencies between with and without malignancies for categorical variables.
ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndromes; ARB = angiotensin receptor blocker; HDL-C = high-density lipoprotein cholesterol; Hs-CRP = high-sensitive C-reactive protein; IQR = interquartile range; LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction; TRS2P = TIMI Risk Score for Secondary Prevention (13).
The no-malignancy group summary statistics are based on patients without malignancy diagnosis prior to death, loss to follow-up or end of the study.